{"analyses":[{"ciLowerLimit":"0.670","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.073","groupDescription":"Hazard ratio was based on stratified Cox regression model with treatment as the only covariate (stratification factors: number of prior cytotoxic chemotherapy regimens, triple negative status, history of central nervous system metastasis status).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1693","paramType":"Hazard Ratio (HR)","paramValue":"0.848","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.6","upperLimit":"22.5","value":"19.3"},{"groupId":"OG001","lowerLimit":"17.4","upperLimit":"22.4","value":"19.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"287"},{"groupId":"OG001","value":"144"}],"units":"Participants"}],"description":"OS was defined as the time (in months) from randomization to death due to any cause. If death was not observed at the time of study cut-off date or permanently lost to follow-up, OS was censored at the date the participant was last known to be alive on or before the study cut-off date, whichever was earlier. The analysis was performed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received talazoparib 1 mg, orally, once daily until radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or sponsor's decision to terminate the trial (up to a maximum of 70.2 months). One cycle was of 21 days.","id":"OG000","title":"Talazoparib"},{"description":"Participants received 1 of the following drugs in specified regimens, as per the physician's choice: 1) capecitabine 1250 mg/m\\^2 orally twice daily on Day 1 to 14 in each cycle; 2) eribulin mesylate 1.4 mg/m\\^2 (equivalent to eribulin 1.23 mg/ m\\^2), as 2 to 5 minute IV infusion on Day 1 and 8 in each cycle; 3) gemcitabine 1250 mg/m\\^2 as 30-minute IV infusion on Day 1 and 8 in each cycle; 4) vinorelbine 30 mg/m\\^2 as 6 to 10 minute IV infusion on Day 1, 8, and 15 in each cycle; until radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or Sponsor's decision to terminate the trial (up to a maximum of 45.3 months). One cycle was of 21 days.","id":"OG001","title":"Physician's Choice Treatment"}],"paramType":"MEDIAN","populationDescription":"ITT analysis population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline until death due to any cause or analysis cut-off, up to a maximum duration of 61.4 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}